BBI Solutions and BioAgilytix Team Up for Efficient Antibody Reagent Production

• BBI Solutions has partnered with BioAgilytix to integrate their services, simplifying a crucial step in bioanalytical testing.

• The partnership will allow customers to work with a single provider for swift access to high-quality, custom antibody reagents.

BBI Solutions has announced a strategic partnership with BioAgilytix, a global bioanalytical laboratory. The partnership aims to integrate BBI’s efficient production of high-quality custom antibody reagents with BioAgilytix’s renowned bioanalytical testing services. This collaboration is set to simplify a crucial step in bioanalytical testing for pharma and biopharma sponsors, ultimately bringing them one step closer to market for their innovative therapies.

Bioanalytical testing is a key aspect of bringing any new therapy to market. Drug developers often require a variety of antibody reagents tailored to their candidate therapy and for a range of testing applications. However, developing and securing a reliable supply of fit-for-purpose, customised antibody reagents is not easy. This step is often managed separately from other aspects of a bioanalytical testing programme, which can further complicate the process.

The new partnership between BioAgilytix and BBI’s antibody development centre, MBS, aims to address this challenge. BBI’s proven, efficient mono- and polyclonal custom antibody reagent development services will be seamlessly integrated with BioAgilytix’s bioanalytical testing solutions. This simplifies the experience for bioanalytical testing customers, who can now work with a single provider for swift access to high-quality, custom antibody reagents suitable across testing applications.

Mathew Hobbs, Chief Commercial Officer at BBI, said, “This partnership further strengthens an already excellent relationship with BioAgilytix through which BBI can utilise the depth of its antibody development expertise to provide custom solutions to its clients. By streamlining a critical and complex step in bioanalytical testing, we’re helping customers get one step closer to delivering their innovative therapies to patients.”

Jim McNally, Ph.D., Chief Scientific Officer at BioAgilytix, added, “BioAgilytix prides itself in its scientist-to-scientist approach to assay development. We work closely with our clients to design highly customised, high-quality bioanalytical assays in close partnership with their scientific teams. This exciting partnership with BBI allows us to expand that relationship and accelerate the assay development process. The scientific team at MBS has always delivered high-quality, high-science customer relationships which are essential to the assay development process. Complex assay development has a clearer path forward with the quality antibodies MBS generates.”